Latest News

MedUni Vienna technology wins Recognition Prize in the science2business awards

A joint project between MedUni Vienna and Freiburg University Hospital, using cyclotides as a treatment for multiple sclerosis, was awarded the Recognition Prize in the science2business awards. This development is an example of a successful transfer of innovation from research to the business world. Read the article published on Medical University of Vienna’s homepage

Read More

Multiple sclerosis: plant peptide could prevent onset of the disease

MedUni Vienna has made a crucial development in the treatment of Multiple Sclerosis (MS): Together with his team and the research group led by Gernot Schabbauer, international partners from Australia, Germany and Sweden, Christian Gruber, Chief Researcher at the Center for Physiology and Pharmacology has demonstrated in an animal model that, following treatment with a […]

Read More

Successful IPO with MedUni Vienna patent

Swedish company Cyxone, a subsidiary of ACCEQUA AB, headquartered in Malmö, recently went public – on the basis of a MedUni Vienna patent application relating to the potential development of an oral medication to combat multiple sclerosis. The invention “Cyclotides as immunosuppressive agents ” is the work of Christian Gruber from the Center for Physiology […]

Read More

Multiple sclerosis: Plant peptide could prevent onset of the disease

https://www.sciencedaily.com/releases/2016/03/160329101244.htm

Read More